Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2021 | Samuraciclib in combination with fulvestrant in patients with advanced HR+/HER2- breast cancer

Charles Coombes, MD, PhD, Imperial College London, London, UK, discusses samuraciclib, a first-in-class, oral, selective inhibitor of CDK7, which was evaluated in combination with fulvestrant in patients with advanced hormone receptor-positive HER2-negative breast cancer. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.